Literature DB >> 18978736

Innovative approaches to treat steroid-resistant or steroid refractory GVHD.

M Berger1, E Biasin, F Saglio, F Fagioli.   

Abstract

First-line treatment of GVHD is based on steroids and produces sustained responses in 50-80% of patients with acute GVHD (aGVHD) and 40-50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with combinations of various agents, but currently available agents have not improved survival in these high-risk populations. In this minireview, we will focus on new agents to treat GVHD in paediatric patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18978736     DOI： 10.1038/bmt.2008.294

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  7 in total

1.  Tocilizumab for steroid refractory acute graft-versus-host disease.

Authors:  Julianna V F Roddy; Bradley M Haverkos; Ali McBride; Kathryn M Leininger; Samantha Jaglowski; Sam Penza; Rebecca Klisovic; William Blum; Sumithira Vasu; Craig C Hofmeister; Don M Benson; Leslie A Andritsos; Steven M Devine; Yvonne A Efebera
Journal:  Leuk Lymphoma       Date:  2015-07-03

2.  Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.

Authors:  M Y Shapira; A Klimov; S Vipul; S Grisariu; B R Avni; R Or; A I Bloom
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

3.  Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-03       Impact factor: 5.742

Review 4.  Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.

Authors:  Jacopo Olivieri; Sabrina Coluzzi; Imma Attolico; Attilio Olivieri
Journal:  ScientificWorldJournal       Date:  2011-10-25

5.  Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation.

Authors:  Julia Drylewicz; Ingrid M M Schellens; Rogier Gaiser; Nening M Nanlohy; Esther D Quakkelaar; Henny Otten; Suzanne van Dorp; Ronald Jacobi; Leonie Ran; Sanne Spijkers; Dan Koning; Rob Schuurman; Ellen Meijer; Floortje L Pietersma; Jurgen Kuball; Debbie van Baarle
Journal:  J Transl Med       Date:  2016-08-02       Impact factor: 5.531

6.  Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.

Authors:  Erica Dander; Paola De Lorenzo; Barbara Bottazzi; Paola Quarello; Paola Vinci; Adriana Balduzzi; Francesca Masciocchi; Sonia Bonanomi; Claudia Cappuzzello; Giulia Prunotto; Fabio Pavan; Fabio Pasqualini; Marina Sironi; Ivan Cuccovillo; Roberto Leone; Giovanni Salvatori; Matteo Parma; Elisabetta Terruzzi; Fabio Pagni; Franco Locatelli; Alberto Mantovani; Franca Fagioli; Andrea Biondi; Cecilia Garlanda; Maria Grazia Valsecchi; Attilio Rovelli; Giovanna D'Amico
Journal:  Oncotarget       Date:  2016-12-13

7.  Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment.

Authors:  Dao-Xing Deng; Shuang Fan; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Xu-Ying Pei; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.